A drug developed as an antidote to the antiplatelet agent ticagrelor safely and effectively reversed ticagrelor's ...

[2] In 1998 only one drug in this class was available, a monoclonal antibody (abciximab) directed against the fibrinogen receptor on the platelet surface GP IIb/IIIa. A more recently approved drug ...

A BLA has been filed for bentracimab and, if approved, has the potential to be the first therapy to reverse the effects of ...

Late-breaking data showed almost all patients achieved normal blood clotting and vessel repair after bentracimab infusion.

“Platelet transfusions are not particularly ... three from the surgery group and two from the major bleeding group — had drug-related adverse events, but there were no serious drug-related ...

An international team of clinical collaborators, led by physician scientists from Dana-Farber Cancer Institute, performed a ...

Class, Polyphosphate (polyP)-Based Therapy, Show Promise in Bypassing P2Y12 Inhibition to Restore Normal Clotting Function ...

In this week’s edition of the biotech bi-weekly, learn more about Thermo Fisher’s new system for automating complex sample ...

While routine treatment with aspirin plus a second anti-clotting drug, known as dual antiplatelet therapy (DAPT), can prevent blood clots, these drugs may increase risk for bleeding, especially ...